Member Info for Hurst10

Spotted the size buyer yet?
Blackrock swapping fund allocation.
Real price 115-20 and then off to the races before more noise.

Wait till post hrs and opening level tomorrow and you can get two keyboards.

Friends of Susquehanna

Size buyer from NY knocking on the door.

Since 12.00 interesting two way trades.

Why did Apollo Endosurgery stock boom today? Agreed to sale to Boston Scientific

APEN +67.83%Nov. 29, 2022 4:30 PM ET
Apollo Endosurgery (NASDAQ:APEN) skyrocketed 67% after Boston Scientific (NYSE:BSX) agreed to purchase the medtech company for $10/share.
Apollo Endosurgery (APEN) traded through the $10/share deal after one analyst said he believed that the company could see a higher offer.
"While takeout has always been our expectation, we are surprised by both the timing and the price," Craig-Hallum analyst Matt Hewitt wrote in a note on Tuesday. Hewitt has a buy rating and $14 price target on APEN wrote in the note.
"Given the size of the market opportunities, we would not be surprised if another offer came in over the coming weeks ..." Hewitt added.
Austin, Texas-based Apollo (APEN) develops products used in endoluminal surgery (ELS), a less-invasive option to open and laparoscopic surgery in patients with gastrointestinal disorders and morbid obesity.
Boston Scientific (BSX) announced an agreement earlier Tuesday to acquire Apollo Endosurgery (APEN) for nearly $615M or $10 per share in an all-cash deal expected to close in 1H 2023.

https://seekingalpha.com/news/3912152-horizon-therapeutics-confirms-takeover-talks-with-several-companies

Another M&A in biotech:

AstraZeneca today announced an agreement to acquire Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts) that offer a novel cell therapy approach for targeting cancer.

Not sure if you saw this:

Our friends at Biocytogen signing up with ADC Therapeutics:
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA (ADCT). Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales.

Our friends at Biocytogen signing up with ADC Therapeutics:
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA (ADCT). Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen’s proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales.

Further to last week’s U-turn from the FDA on several Gene therapy stocks, we have more today :
Sarepta Therapeutics (NASDAQ:SRPT) announced Monday that the FDA accepted its marketing application for gene therapy candidate SRP-9001 it develops with Roche (OTCQX:RHHBY) (OTCQX:RHHBF) under the agency’s priority review.

Avacta’s holding in Affyxell is looking more and more attractive and come an IPO of Affyxell on Nasdaq/Kosdaq, will get a significant re valuation !!!

NY back from extended Thanksgiving break and volume is picking up and the usual parties are on the bid !

Science day and Nasdaq listing

Gene therapy stocks are moving higher this week and easily making new year highs this week. A friendly FDA !!
Biotechs uniQure N.V. and BioMarin Pharmaceutical drove gene therapy developers higher on Wednesday as Wall Street reacted to the companies’ latest regulatory successes.
On Tuesday, the FDA greenlighted Hemgenix, a gene therapy developed by uniQure (QURE) and Australian pharma company CSL Limited (OTCPK:CSLLY) (OTCPK:CMXHF), for certain adults with blood disorder Hemophilia B.
Comment from the Market:
In his comments on the decision, BTIG analyst Yun Zhong said that the approval was largely anticipated, yet it “still provides a highly encouraging catalyst for the gene therapy space in general.”

US Market closing early on Friday at 1pm!
Plenty of time for the usual early coffee and watch Avacta move into new territory on the back of a significant rerating!

Further M&A in the biotech sector:
Merck (NYSE:MRK) has agreed to acquire Imago BioSciences (NASDAQ:IMGO), a clinical-stage biotech focused on bone marrow disorders, for $36.00 per share in cash, indicating a total equity value of $1.35B, the companies announced Monday.

Worth giving the JV between LG Chem and Avacta a second Look.
Affimer PD-L1 moving forward to pre clinical targeted immunotherapy and the proposed assistance of AI, for an excellent PD-L1 scoring.
Avacta and LG and the introduction of AI could lift the scoring concordance to excellent!

Novartis to dispose of non core assets, raising funds to invest in cutting edge medicine.

I would argue that the arrival of Heights Capital Management/ Susquehanna on the shareholder list creates a triple A US investor list and tremendous support for a Nasdaq listing of the Therapeutic business, rolling out the AVA6000 ,AVA3396 and family!!
It will be the IPO of the year and buying the U.K. listing now makes it even more attractive.
Thermo Fisher will be over the Diagnostic business.
Picking up stock below 140 pre US opening is an early Christmas present.
Watch the buying picking up pace pre NY , with the usual MM’s trying to control the bid.
Elliott Management joining their friends at Susquehanna !!

Good size buy volume post hours and some size sale tickets as well.